Biogen

News

Closeup of X-ray photography of human brain

Biogen's Alzheimer's drug Aduhelm is rejected by EU advisors

The EMA's human medicines committee has said it cannot approve Biogen and Eisai's Alzheimer's disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug.

News

Biogen updates on its confirmatory Aduhelm trial

Biogen and partner Eisai have said they will provide details next March for the confirmatory trial that will be needed to upgrade the drug's accelerated approval for controversial Alzheimer

News

Biogen puts $15m into digital health alliance with TheraPana...

Biogen has made a $15 million investment in digital health company TheraPanacea, which will go towards a project to find digital health tools aimed at neurological diseases.

News

CHMP minded to turn down Alzheimer's drug Aduhelm, says Biog...

Biogen and Eisai have said that the EMA's human medicines committee looks unlikely recommended approval of their Alzheimer's drug Aduhelm when it comes up for discussion next month.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

AbbVie's Humira tops ICER's list of unwarranted price hikes ...

With drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and Economic Review (ICER) has published its third report on "unsupported" price i

News